|
HY-150233-1mg
|
MedChemexpress LLC
|
Cys-McMMAF [CAS 1160590-05-5]
|
|
Cancer-programmed cell death
|
|
|
HY-150233-10mg
|
MedChemexpress LLC
|
Cys-McMMAF [CAS 1160590-05-5]
|
|
Cancer-programmed cell death
|
|
|
HY-150233-5mg
|
MedChemexpress LLC
|
Cys-McMMAF [CAS 1160590-05-5]
|
|
Cancer-programmed cell death
|
|
|
HY-P99163-1mg
|
MedChemexpress LLC
|
Tilavonemab [CAS 2096513-89-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99163-10mg
|
MedChemexpress LLC
|
Tilavonemab [CAS 2096513-89-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99163-5mg
|
MedChemexpress LLC
|
Tilavonemab [CAS 2096513-89-0]
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P99178-1mg
|
MedChemexpress LLC
|
CTX-471 [CAS 2377152-49-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99178-10mg
|
MedChemexpress LLC
|
CTX-471 [CAS 2377152-49-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99178-5mg
|
MedChemexpress LLC
|
CTX-471 [CAS 2377152-49-1]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99248-1mg
|
MedChemexpress LLC
|
Risankizumab [CAS 1612838-76-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99248-10mg
|
MedChemexpress LLC
|
Risankizumab [CAS 1612838-76-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99248-5mg
|
MedChemexpress LLC
|
Risankizumab [CAS 1612838-76-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99276-1mg
|
MedChemexpress LLC
|
Abagovomab [CAS 792921-10-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99276-5mg
|
MedChemexpress LLC
|
Abagovomab [CAS 792921-10-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P9934-1mg
|
MedChemexpress LLC
|
Abciximab [CAS 143653-53-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P9934-10mg
|
MedChemexpress LLC
|
Abciximab [CAS 143653-53-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P9934-5mg
|
MedChemexpress LLC
|
Abciximab [CAS 143653-53-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99351-1mg
|
MedChemexpress LLC
|
Andecaliximab [CAS 1518996-49-0]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99351-10mg
|
MedChemexpress LLC
|
Andecaliximab [CAS 1518996-49-0]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99351-5mg
|
MedChemexpress LLC
|
Andecaliximab [CAS 1518996-49-0]
|
|
Cancer-Kinase/protease
|
|
|
HY-P99395-1mg
|
MedChemexpress LLC
|
Talacotuzumab [CAS 1826831-79-1]
|
|
Cancer-programmed cell death
|
|
|
HY-P9954-1mg
|
MedChemexpress LLC
|
Catumaxomab [CAS 509077-98-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P9954-10mg
|
MedChemexpress LLC
|
Catumaxomab [CAS 509077-98-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P9954-5mg
|
MedChemexpress LLC
|
Catumaxomab [CAS 509077-98-9]
|
|
Cancer-programmed cell death
|
|
|
HY-P99604-1mg
|
MedChemexpress LLC
|
Cilgavimab [CAS 2420563-99-9]
|
|
|
|
